Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

• Forschungsstelle: INNOSUISSE
• Projektnummer: 100.087 IP-LS
• Projekttitel Englisch: Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Schlüsselwörter (Englisch)

Life sciences, Pharmaceuticals

Abstract (Englisch)

Idiopathic pulmonary fibrosis (IPF) is a form of restrictive interstitial lung disease (ILD) associated with extremely poor outcomes. With our approach based on a unique mode of action drug that restores cGMP levels, we aim to stop lung fibrosis progression and increase the survival rate.